263 related articles for article (PubMed ID: 25727667)
1. The effects of atorvastatin treatment on the mean platelet volume and red cell distribution width in patients with dyslipoproteinemia and comparison with plasma atherogenicity indicators--A pilot study.
Kucera M; Balaz D; Kruzliak P; Ciccocioppo R; Oravec S; Rodrigo L; Zulli A; Hirnerova E; Sabaka P; Komornikova A; Sabo J; Slezak P; Gaspar L
Clin Biochem; 2015 Jun; 48(9):557-61. PubMed ID: 25727667
[TBL] [Abstract][Full Text] [Related]
2. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
3. Effect of atorvastatin on low-density lipoprotein subpopulations and comparison between indicators of plasma atherogenicity: a pilot study.
Kucera M; Oravec S; Hirnerova E; Huckova N; Celecova Z; Gaspar L; Banach M
Angiology; 2014 Oct; 65(9):794-9. PubMed ID: 24163116
[TBL] [Abstract][Full Text] [Related]
4. Low-density lipoprotein cholesterol-to-apolipoprotein B ratio as a potential indicator of LDL particle size and plasma atherogenicity in type 2 diabetes.
Viktorinova A; Malickova D; Svitekova K; Choudhury S; Krizko M
Diabetes Res Clin Pract; 2021 Jun; 176():108858. PubMed ID: 34015391
[TBL] [Abstract][Full Text] [Related]
5. Effect of atorvastatin on hematologic parameters in patients with hypercholesterolemia.
Akin F; Ayça B; Köse N; Sahin I; Akin MN; Canbek TD; Güngör O
Angiology; 2013 Nov; 64(8):621-5. PubMed ID: 23460112
[TBL] [Abstract][Full Text] [Related]
6. Red blood cell distribution width and mean platelet volume: Surrogate markers for, or treatment targets in, dyslipidemia?
Lippi G
Clin Biochem; 2015 Jun; 48(9):555-6. PubMed ID: 25910581
[No Abstract] [Full Text] [Related]
7. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study.
Wolffenbuttel BH; Franken AA; Vincent HH;
J Intern Med; 2005 Jun; 257(6):531-9. PubMed ID: 15910557
[TBL] [Abstract][Full Text] [Related]
8. Association of red blood cell distribution width with plasma lipids in a general population of unselected outpatients.
Lippi G; Sanchis-Gomar F; Danese E; Montagnana M
Kardiol Pol; 2013; 71(9):931-6. PubMed ID: 24065422
[TBL] [Abstract][Full Text] [Related]
9. The effects of treatment on lipoprotein subfractions evaluated by polyacrylamide gel electrophoresis in patients with autoimmune hypothyroidism and hyperthyroidism.
Minarikova Z; Gaspar L; Kruzliak P; Celecová Z; Oravec S
Lipids Health Dis; 2014 Oct; 13():158. PubMed ID: 25300222
[TBL] [Abstract][Full Text] [Related]
10. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS
Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
Balasubramanian R; Varadharajan S; Kathale A; Nagraj LM; Periyandavar I; Nayak UP; Sharma A; Bolmall C; Baliga VP
J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505
[TBL] [Abstract][Full Text] [Related]
12. Clinical usefulness of mean platelet volume and red blood cell distribution width to platelet ratio for predicting the severity of hepatic fibrosis in chronic hepatitis B virus patients.
Karagoz E; Ulcay A; Tanoglu A; Kara M; Turhan V; Erdem H; Oncul O; Gorenek L
Eur J Gastroenterol Hepatol; 2014 Dec; 26(12):1320-4. PubMed ID: 25210777
[TBL] [Abstract][Full Text] [Related]
13. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia.
Gumprecht J; Gosho M; Budinski D; Hounslow N
Diabetes Obes Metab; 2011 Nov; 13(11):1047-55. PubMed ID: 21812889
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA
Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066
[TBL] [Abstract][Full Text] [Related]
15. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
16. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
[TBL] [Abstract][Full Text] [Related]
17. The apolipoprotein B/apolipoprotein A-I ratio as a potential marker of plasma atherogenicity.
Kaneva AM; Potolitsyna NN; Bojko ER; Odland JØ
Dis Markers; 2015; 2015():591454. PubMed ID: 25852220
[TBL] [Abstract][Full Text] [Related]
18. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study.
Farsang C; Athyros V; Gaw A;
Curr Med Res Opin; 2007 Aug; 23(8):1945-56. PubMed ID: 17626713
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of the LDL-C/apoB ratio in the overall evaluation of atherogenicity of lipid profile.
Kaneva AM; Potolitsyna NN; Bojko ER
Arch Physiol Biochem; 2017 Feb; 123(1):16-22. PubMed ID: 27347637
[TBL] [Abstract][Full Text] [Related]
20. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
